MedTrace Logo

AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)

NCT07584317 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1170

Last updated 2026-05-13

No results posted yet for this study

Summary

This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in HCC.

Conditions

Interventions

OTHER

Artificial Intelligence

Investigators utilize a AI-based supportive system to predict clinical outcomes for patients with hepatocellular carcinoma who received TACE combined with immunotherapy and targeted therapy

Sponsors & Collaborators

  • Gao-jun Teng

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-18
Primary Completion
2027-05-31
Completion
2028-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07584317 on ClinicalTrials.gov